Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer-Reference-Cited by-同舟云学术

Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer

Published:2014-04-18 Issue:16 Volume:120 Page:2424-2431
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Bachir Bassel G.¹,Dragomir Alice¹,Aprikian Armen G.¹,Tanguay Simon¹,Fairey Adrian²,Kulkarni Girish S.³⁴,Breau Rodney H.⁵,Black Peter C.⁶,Kassouf Wassim¹⁷

Affiliation:

1. Division of Urology, Department of Surgery; McGill University Health Center; Montreal Quebec Canada

2. Division of Urology, Department of Surgery, Faculty of Medicine; University of Alberta; Edmonton Alberta Canada

3. Division of Urology, Department of Surgery; University Health Network, University of Toronto; Toronto Ontario Canada

4. Institute for Clinical and Evaluative Sciences, University of Toronto; Toronto Ontario Canada

5. Division of Urology, Clinical Epidemiology; Ottawa Hospital Research Institute; Ottawa Ontario Canada

6. Department of Urologic Sciences; University of British Columbia; Vancouver British Columbia Canada

7. McGill Urology Residency Program Director; McGill University Health Center; Montreal Quebec Canada

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28731/fullpdf

Reference26 articles.

1. European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013;Babjuk;Eur Urol,2013

2. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial;Stasi;Lancet Oncol,2006

3. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations;Laupacis;CMAJ,1992

4. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study;Lamm;J Urol,2000

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems;Pharmaceutics;2023-12-03

2. Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature;PharmacoEconomics;2023-04-23

3. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer;Urologic Oncology: Seminars and Original Investigations;2023-04

4. Biodegradable ring-shaped implantable device for intravesical therapy of bladder disorders;Biomaterials;2022-09

5. Health economic analyses of secondary vaccine effects: a systematic review and policy insights;Expert Review of Vaccines;2022-01-12